|  |  |
| --- | --- |
| Minutes  Drug Utilization Review Board Meeting  DATE: March 14, 2024 |  |



**Meeting Purpose:** Quarterly Drug Utilization Board Meeting

Meeting opened at 6:00 p.m. by Timothy Fensky, RPh.

The meeting was conducted under Massachusetts Public Meeting Law requirements.

**Attendance:** Mehmet Furkan Burbak, MD; Melissa Coyle, PharmD; Timothy Fensky, RPh; Colleen Labelle, MSN, RN-BC, CARN; Lori Lewicki, RPh; Sarah M McGee, MD; Laura Spring, MD; Karen Ryle, MS, RPh; Christy Stine, MD, PhD

**Absent:** Rebekah Rice, RPh, CDCES

**Agenda Items:**

* Welcome and Introductory Remarks
* Guest Speakers
* Minutes
* Annual Pipeline Continuing Education Program
* Pediatric Behavioral Health Medication Initiative Quality Assurance Analysis
* MHDL Update
* **DUR Operational Update**
* **MassHealth Update**
* **Open Forum**

|  |  |  |
| --- | --- | --- |
| **Agenda Item** | **Discussion** | **Conclusions/Follow Up** |
| **Guest Speakers** | * Daniel Bassoff, Medical Knowledge Care Team at Sarepta Therapeutics, spoke on Elevidys. * Jennifer Handt, parent, spoke on Elevidys. * Brian Denger, parent and advocate at Parent Project Muscular Dystrophies, spoke on Elevidys. | **Follow Up**  Informational/Advisory |

|  |  |  |
| --- | --- | --- |
| **Agenda Item** | **Discussion** | **Conclusions/Follow- up** |
| **Minutes** | Motion to approve the minutes for December 2023 was made by Christy Stine, MD, PhD and seconded by Timothy Fensky, RPh. | **Follow-up**  Minutes are approved. |

| **Agenda Item** | **Discussion** | **Conclusions/Follow- up** |
| --- | --- | --- |
| **Annual Pipeline Continuing Education Program** | Annual Pipeline Continuing Education by Dr. Collin Jerrard and Dr. Anhar Eldesouky  The Pipeline Updated provided an overview of clinical and/or regulatory updates regarding select pharmaceutical pipeline agents in late-stage development. | **Follow-up**  Informational/Advisory |
| Action | Discussion   * Described recent trends in the FDA approval process * Compared and contrasted the emerging pipeline agents with current available therapeutic options * Summarized biosimilar product availability of reference agents over the coming year   Conclusions   * Immuno-oncology drugs continued to lead the pack for pipeline drug development. * Cell and gene therapy approvals continued to accelerate as the number of clinical trials trend upward. * Biosimilar adoption has been slow, due to numerous factors, such as the COVID-19 pandemic and provider/patient familiarity with reference products. | **Conclusion**  The board reviewed and accepted the presentation. |

| **Agenda Item** | **Discussion** | **Conclusions/Follow- up** |
| --- | --- | --- |
| **Pediatric Behavioral Health Medication Initiative Quality Assurance Analysis** | Pediatric Behavioral Health Medication Initiative Quality Assurance Analysis by Dr. Ashley Chiara  This overview was an evaluation of current medical literature and provided a brief overview of new guideline recommendations in this disease state. | **Follow-up**  Informational/Advisory |
| Action | Discussion   * Reviewed the background of PBHMI, existing management, and Therapeutic Class Management (TCM) workgroup involvement * Discussed recent quality management improvement (QI) and quality assurance (QA) efforts * Reviewed the annual pediatric behavioral medication utilization data * Outlined the recommended updates and changes to PBHMI restrictions and prior authorization (PA) criteria   Recommendations   * Update antipsychotic age PA criteria * Update interclass polypharmacy PA criteria * Update specialist PA criteria | **Conclusion**  The board reviewed and accepted the presentation. |

| **Agenda Item** | **Discussion** | **Conclusions/Follow- up** |
| --- | --- | --- |
| **MassHealth Drug List (MHDL) Update** | MHDL Update by Dr. Bon Van  MHDL overview included new additions, changes in PA status, and related attachment updates to be implemented with a recent publication rollout. | **Follow-up**  Informational/Advisory |
| Action | Discussion   * There was one addition to the MHDL Drug list effective April 1, 2024. * As of April 1, 2024, there were four agents added to the MassHealth Supplemental Rebate/Preferred Drug List, as well as additional changes to the MassHealth Acute Hospital Carve-Out Drugs List. * There were 17 additions to PA status to the MHDL Drug list effective May 6, 2024. Sixteen will require PA while one will not. * There were several changes to Coverage Status for Pharmacy Billing, Brand Name Preferred Over Generic List; 90-day Initiative; Over the Counter Drug List; Quick Reference Guide; Pharmacy Covered Professional Services List; and Preferred Non-Drug Products Listing | **Conclusion**  The board reviewed and accepted the presentation. |

| **Agenda Item** | **Discussion** | **Conclusions/Follow- up** |
| --- | --- | --- |
| **DUR Operational Update** | DUR Operational Update by Dr. Patricia Leto  DUR operational overview included statistics associated with PA review and PA response, and call center metrics. | **Follow-up**  Informational/Advisory |
| Action | Discussion   * Operational statistics, including PA and call center metrics up to December 31, 2024, were discussed. * All metrics met or exceeded service level agreements. | **Conclusion**  The board reviewed and accepted the presentation. |

| **Agenda Item** | **Discussion** | **Conclusions/Follow- up** |
| --- | --- | --- |
| **MassHealth Update** | MassHealth Update by Dr. Kimberly Lenz  MassHealth Update is a summary of recent developments in MassHealth in the context of pharmacy, managed care, or public health. | **Follow-up**  Informational/Advisory |
| Action | Discussion   * Reviewed current clinical program initiatives * Provided direct negotiation status update * Discussed operational updates | **Conclusion**  The board reviewed and accepted the presentation. |

| **Agenda Item** | **Discussion** | **Conclusions/Follow- up** |
| --- | --- | --- |
| **Open Forum** | Open Forum | **Follow-up**  Informational/Advisory |
| Action | Discussion   * This presentation was tabled until the next DUR Board meeting. | **Conclusion**  N/A |

Meeting adjourned at 8:00 p.m.

Respectfully submitted by Mylissa Price

Date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_